Search Back New search Go to resultsDiseaseMain groupHematological Diseases, Non-MalignantProtocol groupAnemias, CytopeniasHemolytic DiseasesDiseaseParoxysmal Nocturnal HemoglobinuriaSubgroupICD10D59.5MeSHHemoglobinuria, ParoxysmalSequenceChemotherapyChemo-substancePegcetacoplanChemo-substancePegcetacoplanChemo-substancePegcetacoplanChemo-substancePegcetacoplanNo. Substances1 RadiotherapySupportive therapySupportive substanceBalanced Crystalloid SolutionRavulizumabSupportive substanceBalanced Crystalloid SolutionRavulizumabSupportive substanceBalanced Crystalloid SolutionRavulizumabSupportive substanceBalanced Crystalloid SolutionRavulizumabNo. Substances2Protocol classificationTherapy classificationcurrent standardIntensityStandard doseTherapy indicationSecond lineseveral possibleTherapy phaseInductionMaintenanceTherapy intentiondisease controlRisksAnemia Hb below 10g/dlAstheniaConstipationDiarrheaHematotoxicityNasopharyngitisNauseaPainPyrexiaRashUpper Respiratory Tract Infection only studiesPublicationAuthorHillmen PLee J / Kulasekararaj ADiseasePNH, Erst-oder Zweitlinie nach EculizumabPNH mit Hämoglobin < 10,5g/dl während 3 Monaten EculizumabOrigin301/302 studyBexley Wing, St. James’s University Hospital, Leeds, United Kingdom, Pegasus trialProtocols in Revision 3 protocols foundProtocols under revision.Pegcetacoplan 1080, Paroxysmal Nocturnal Hemoglobinuria (PID1928 V1.0)Ravulizumab 2700, Paroxysmal Nocturnal Hemoglobinuria, Induction (PID1449 V1.0)Ravulizumab 3300, Paroxysmal Nocturnal Hemoglobinuria, maintenance (PID1450 V1.0)
